"versionIdentifier","studyTitle","rationale","uuid:ID","id","studyAcronym"
"2","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","eb7eb3c7-2a0f-4473-b5e3-709cc673a97c","StudyVersion_1","LZZT"
